25-Hydroxyvitamin D3 1α-hydroxylase expression in breast cancer and use of non-1α-hydroxylated vitamin D analogue
2005

Vitamin D and Breast Cancer: Exploring 1α-Hydroxylase Expression

Sample size: 29 publication Evidence: moderate

Author Information

Author(s): Ulrika Segersten, Pernille Kaae Holm, Peyman Björklund, Ola Hessman, Hans Nordgren, Lise Binderup, Göran Åkerström, Per Hellman, Gunnar Westin

Primary Institution: Uppsala University Hospital

Hypothesis

The study investigates the expression of 1α-hydroxylase in breast cancer and the biological function of a non-1α-hydroxylated vitamin D analogue.

Conclusion

The study found normal expression levels of 1α-hydroxylase, 24-hydroxylase, and VDR in most breast cancer specimens, and a non-1α-hydroxylated vitamin D analogue showed activity in breast cancer cells.

Supporting Evidence

  • 1α-hydroxylase was expressed in 79% of breast cancer specimens.
  • The VDR was expressed in 95% of the tumors.
  • The non-1α-hydroxylated vitamin D analogue EB1285 activated transcription in MCF-7 cells.

Takeaway

Researchers looked at how a certain vitamin D enzyme works in breast cancer and found that a special vitamin D treatment could help fight the disease.

Methodology

The study used immunohistochemistry and RT-PCR to analyze the expression of 1α-hydroxylase, 24-hydroxylase, and VDR in breast cancer and normal tissues.

Limitations

The study was limited by the small sample size and the specific types of breast cancer examined.

Participant Demographics

The study included 19 breast cancer specimens (17 invasive ductal carcinoma and 2 invasive lobular carcinoma) and 10 normal breast tissue specimens.

Statistical Information

P-Value

p < 0.001

Statistical Significance

p < 0.001

Digital Object Identifier (DOI)

10.1186/bcr1332

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication